Amalgamated Bank Sells 3,208 Shares of DexCom, Inc. (NASDAQ:DXCM)

Amalgamated Bank decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 80,906 shares of the medical device company’s stock after selling 3,208 shares during the quarter. Amalgamated Bank’s holdings in DexCom were worth $6,292,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. Sentry Investment Management LLC raised its stake in DexCom by 131.6% during the fourth quarter. Sentry Investment Management LLC now owns 4,340 shares of the medical device company’s stock worth $337,000 after buying an additional 2,466 shares during the last quarter. Brown Financial Advisors grew its holdings in DexCom by 35.6% during the 4th quarter. Brown Financial Advisors now owns 14,632 shares of the medical device company’s stock worth $1,138,000 after acquiring an additional 3,839 shares during the period. Rothschild Investment LLC grew its holdings in DexCom by 250.5% during the 4th quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after acquiring an additional 536 shares during the period. HealthInvest Partners AB raised its position in shares of DexCom by 11.7% in the 4th quarter. HealthInvest Partners AB now owns 60,057 shares of the medical device company’s stock worth $4,684,000 after acquiring an additional 6,300 shares in the last quarter. Finally, Midwest Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at about $54,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $89.91 on Thursday. The firm has a market capitalization of $35.13 billion, a P/E ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a 50 day moving average price of $84.29 and a two-hundred day moving average price of $76.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. Wells Fargo & Company raised their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.